Beth LeBow
Lawyers
Filters
Eargo $165.2 million IPO
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 9,029,629 shares of common stock of Eargo, Inc. at $18.00 per share …
Carvana $1.1 billion senior notes offering
Davis Polk advised the representative of the initial purchasers on a Rule 144A/Regulation S debt offering by Carvana Co. of $500 million aggregate principal amount of its 5.625%…
Rackspace Technology $600 million cash tender offer
Davis Polk advised the dealer manager in connection with a cash tender offer by Rackspace Technology Global, Inc., an indirect subsidiary of Rackspace Technology, Inc., for up to $600…
Etsy $650 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Etsy, Inc. of $650 million aggregate principal amount of its 0.125% convertible senior notes due…
Berkeley Lights $204.9 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of Berkeley Lights, Inc. at $22.00 per share (which includes the…
NetApp $2 billion notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by NetApp, Inc. of $750 million aggregate principal amount of its 1.875%…
Applied Materials $1.5 billion notes offering
Davis Polk advised the underwriters in connection with an SEC-registered offering by Applied Materials, Inc. of $750 million aggregate principal amount of its 1.750% notes due 2030 and $750…
AtriCure $201.2 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC-registered follow-on offering of 4,573,863 shares of common stock…
Revolution Medicines $273.7 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…
Revance Therapeutics $287.5 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…